Amicus Therapeutics Inc (NASDAQ: FOLD) has reported a loss for its fourth fiscal quarter (ending December 31) of $-0.11 versus a loss $-0.19 for the same period a year ago. This result fell short of the consensus estimate of $-0.04 by $-0.07. For the latest four quarters through December 31, E.P.S. were $-0.51 versus $-0.82 for the same period a year ago.
Recent Price Action
Amicus Therapeutics Inc (NASDAQ: FOLD) stock suffered a large decline of -6.5% on 2/28/24. The stock closed at $12.95. Moreover, trading volume in this decline was unusually high at 173% of normal. The stock has declined -5.5% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
FOLD is expected to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Amicus Therapeutics has a very low Appreciation Score of 2 but a neutral Power Rating of 55, producing the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment